This post is presented by our media partner Cannabis News Wire
View the original article here.
- Diabetes – Blood glucose levels reduced by 19.9% with patented DehydraTECH(TM) processed CBD
- Epilepsy – Lower dosages of DehydraTECH-CBD were needed to achieve the same results of Epidiolex(R) in the company’s animal epilepsy study
- Dementia – Lexaria determined that a longer testing duration is needed for DehydraTECH-CBD in cognition studies
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, including the company’s patented DehydraTECH(TM) technology, recently reported additional findings from its diabetes animal study DIAB-A22-1, as well as updates on two other applied R&D programs for dementia (DEM-A22-1) and epilepsy (EPIL-A21-1).
In March, Lexaria announced that it had completed initial testing using DehydraTECH-CBD in its diabetes animal model study. It initially produced three positive outcomes, including weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels. After the initial testing, Lexaria undertook an additional round of analysis to explore other study outcomes, including using an additional blood glucose assay detection system with higher detection sensitivity than was used in the first round of testing.
Using the Antech hexokinase blood chemistry test panel methodology, the company discovered that blood glucose levels were statistically significantly lowered by 19.9 ± 7% in the obese diabetic-conditioned animals treated with the DehydraTECH-CBD 30 mg/Kg dose. This finding appears to be a discovery of a property not generally known to be associated with generic CBD treatment. The findings in DIAB-A22-1 and DehydraTECH-CBD’s ability to reduce animal blood sugar levels are extremely encouraging for Lexaria and warrant additional research.
Lexaria announced dementia study DEM-A22-1 in November 2022 to investigate whether DehydraTECH-CBD enables pro-cognitive performance enhancements in its model, potentially for use in dementia treatment. Although findings were generally unremarkable and several unexpected study complications may have muted efficacy distinction ability, the company recognizes that previous research by other investigators using CBD in this animal model has required dosing over a longer duration. Lexaria will consider this if further testing is considered in the future – including with DehydraTECH-processed nicotine as another agent known to enhance cognitive performance when delivered effectively.
Also announced in November 2022, Lexaria completed two parts of its EPIL-A21-1 study designed to evaluate the effectiveness of DehydraTECH-CBD in comparison to one of the world’s leading anti-seizure medications, Epidiolex(R), in reducing seizure activity using an established, vehicle-controlled, acute animal seizure model induced by electrical stimulation. Findings of the initial study appear to demonstrate that DehydraTECH-CBD had effectiveness at lower dosages and faster than Epidiolex(R).
Since the initial announcement, Lexaria has completed the final electrical stimulation study under EPIL-A21-1, which was designed to establish an ED50 (the dose required to achieve seizure inhibition in 50% of the animals tested) for DehydraTECH-CBD in this animal model. This ED50 study was designed to corroborate prior findings.
Lexaria was able to confirm that the outcome demonstrated that DehydraTECH-CBD was most effective at a dose of 75 mg/Kg, also as previously reported from the initial round of work in this animal model, which compared favorably to Epidiolex(R), which generally requires a higher dose of 100 mg/Kg to achieve the same results.
Since the development of DehydraTECH in 2014, Lexaria has yielded 34 granted patents, with many more pending patents in countries worldwide. The benefits of using this patented technology include the delivery of bioactive substances via oral ingestion without the need for unhealthy practices of inhalational dosing and without the need for co-administration with unhealthy sugars or sweeteners commonly used to mask bitter tastes. Lexaria is testing its technology for various indications and needs currently unmet by available medical treatments.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cannabisnewswire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
This post was originally published by our media partner here.
